Encephalopathy Induced by Preventive Administration of Acyclovir in a Man with Symptomatic Multiple Myeloma and Renal Dysfunction
Open Access
- 1 February 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in International Journal of General Medicine
- Vol. ume 14, 413-417
- https://doi.org/10.2147/ijgm.s291320
Abstract
Background: Acyclovir (ACV) neurotoxicity is a neuropsychiatric condition induced by the anti-herpetic drugs ACV and valacyclovir (VACV). It is presumed that elevated blood levels of ACV and its metabolite 9-carboxymethoxymethylguanine are involved in the development of ACV-induced encephalopathy; age and renal dysfunction are risk factors. Here, we report a case of encephalopathy caused by the administration of VACV for herpes zoster prophylaxis in a patient with renal dysfunction owing to multiple myeloma. Case Presentation: Renal dysfunction was diagnosed in a 70-year-old man visiting our hospital for a medical checkup. His creatinine clearance rate was 8 mL/min. He was diagnosed with symptomatic multiple myeloma, and bortezomib/dexamethasone (BD) therapy for multiple myeloma and VACV for herpes zoster prophylaxis were initiated. We administered 500 mg/day of VACV three times a week, a lower dosage than recommended, after adjusting for his renal impairment. His renal function was monitored twice per week during therapy. During the second course of BD therapy, 6 weeks after starting treatment, he was hospitalized owing to impaired consciousness (Glasgow Coma Scale score: E2, V4, M4), and his BD and VACV therapy were suspended. Brain magnetic resonance imaging and cerebrospinal fluid analysis showed no abnormalities. Three days after discontinuing BD and VACV therapy, his consciousness recovered completely, and impaired consciousness did not recur after resuming BD therapy. His clinical diagnosis was thus ACV-induced encephalopathy. Conclusion: VACV is often prescribed to patients with multiple myeloma receiving BD therapy to prevent herpes zoster. ACV-induced encephalopathy is commonly observed in patients with renal dysfunction; especially among patients with multiple myeloma with Bence–Jones proteinuria, renal tubules are easily damaged and plasma ACV concentrations are likely to increase and induce ACV-induced encephalopathy. Careful monitoring of the level of consciousness is necessary during preventive ACV therapy in patients with renal dysfunction.Keywords
This publication has 12 references indexed in Scilit:
- Acyclovir-Induced NeurotoxicityClinical Journal of Sport Medicine, 2016
- Herpes zoster encephalopathy or acyclovir neurotoxicity: a management dilemmaBMJ Case Reports, 2014
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III TrialJournal of Clinical Oncology, 2010
- Valacyclovir neurotoxicity: clinical experience and review of the literatureEuropean Journal of Neurology, 2009
- Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX StudyJournal of Clinical Oncology, 2008
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaThe New England Journal of Medicine, 2008
- Adverse neuropsychiatric effects of cytomegalovirus prophylaxis with valaciclovir in renal transplant recipientsNephrology Dialysis Transplantation, 2006
- Acyclovir Neurotoxicity: Clinical Experience and Review of the LiteratureSouthern Medical Journal, 1994
- Distinguishing acyclovir neurotoxicity from encephalomyelitisJournal of Internal Medicine, 1993
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981